B ortezomib (PS-341), a potent and selective proteasome inhibitor, targets the ubiquitin-proteasome pathway. 1 It is active as a single agent and potentiates chemotherapy and radiation in preclinical models. 2 Bortezomib is approved by the Food and Drug Administration for the treatment of second-line multiple myeloma and mantle cell lymphoma. Early phase clinical studies have demonstrated tolerability and activity in a variety of hematologic malignancies and solid tumors. By its mechanism of inhibiting protein degradation, bortezomib targets a wide range of pathways that are relevant to tumor progression and therapy resistance and can directly modulate expression of cyclins, p27 Kip1 , p53, NF-B, Bcl-2, and Bax. 3 Preclinical data suggest that proteasome inhibition may reverse platinum resistance, which is a common cause of treatment failure and disease progression in many solid tumors, although its mechanism is not known. 4 Although bortezomib has shown its greatest benefit in the treatment of relapsed multiple myeloma, it targets many key cell cycle regulators that are relevant to tumor progression and therapy resistance in solid tumors like lung cancer. 5, 6 The ability of bortezomib to favorably modulate the expression of apoptosis-associated proteins, along with its moderate toxicity as a single agent, provides the basis for its combination with cytotoxic agents.
Pemetrexed is a novel, multi-targeted antifolate that inhibits at least three of the enzymes involved in folate metabolism (thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase) and purine and pyrimidine synthesis. Pemetrexed has demonstrated broad anti-tumor activity in a wide variety of solid tumors. 7 Its most significant toxicities include myelosuppression and mucositis, although these toxicities have been significantly reduced with supplementation of folate and vitamin B12 without affecting efficacy. Based on data from randomized phase III trials, pemetrexed has been approved for use in mesothelioma in combination with cisplatin and as a single agent in previously treated non-small cell lung cancer (NSCLC). 8, 9 Bortezomib's novel mechanism of action and efficacy against a number of malignancies makes it an attractive agent to be combined with another targeted agent like pemetrexed. Bortezomib would be expected to synergize with chemotherapy as a result of its ability to lower the apoptotic threshold of cancer cells and has been empirically combined with pemetrexed in this study. It is hypothesized that the combination of pemetrexed and bortezomib can be administered safely in patients with advanced solid tumors without a significant increase in toxicity.
PATIENTS AND METHODS

Patient Selection
Patients with histologically or cytologically diagnosed advanced solid tumors were eligible. Other eligibility criteria included: age older than 18 years, life expectancy longer than 12 weeks, performance status 0 -2, and any number of prior chemotherapy regimens. Adequate hematologic, renal, and hepatic function were required. Patients with asymptomatic treated brain metastasis were eligible for this trial if they were neurologically stable and had been off steroids for at least 4 weeks. Because of possible bortezomib-related neurotoxicity, patients with preexisting neuropathy grade 2 or greater were not eligible to participate. Patients who had previously received pemetrexed or bortezomib were excluded. If patients were taking nonsteroidal antiinflammatories or salicylates, they were required to stop the medication from the day before until the day after receiving pemetrexed because of potential interaction. The institutional review boards at University of California Davis Campus and Veterans Affairs Contra Costa Regional Medical Center approved this study. All patients gave written informed consent.
Dose-Limiting Toxicity and Maximal Tolerated Dose Definitions
A dose-limiting toxicity (DLT) was defined as any of the following that occurred within the first cycle of treatment: grade 4 thrombocytopenia or grade 3 thrombocytopenia associated with bleeding, requirement for transfusion, or lasting longer than 7 days; febrile neutropenia; grade 3 neutropenia associated with a documented infection; or any other grade 3 or greater non-hematologic toxicity considered by the investigator to be related to study drug. Toxicity was graded according to the NCI Common Toxicity Criteria Adverse Events (NCI CTCAE) V 3.0.
All patients treated at a particular dose level were observed for a minimum of 21 days after the start of the first course (i.e., the length of the treatment cycle) before accrual to the next dose level was allowed. No intra-patient dose escalation was allowed.
Patients were accrued in cohorts of three patients per dose level. If none of the three patients experienced a DLT, three patients were treated at the next dose level. If DLT attributable to the treatment was experienced in one of three patients, three more patients (for a total of six patients) were treated at that dose level. If no additional DLT was observed at the expanded dose level (i.e., one of six with DLT), the dose was escalated. Escalation terminated as soon as two or more patients experienced any DLT attributable to study drugs at a given dose level.
The maximal tolerated dose (MTD) was defined as the highest dose level at which no more than one patient experienced a DLT when at least six patients were treated at that dose and were evaluable for toxicity or when the final dose level was reached.
Treatment Plan
The treatment schema is represented in Table 1 , and the dose escalation scheme is summarized in Table 2 . Patients were treated on one of two treatment arms, A or B. Accrual to treatment arm A was independent of accrual to treatment arm B.
In arm A, pemetrexed was administered intravenously on day 1 of a 21-day cycle, and bortezomib was given intravenously on day 1, 60 minutes after the pemetrexed infusion, then on days 4, 8 and 11. In arm B, pemetrexed was delivered intravenously on day 1 of a 21-day cycle, and bortezomib was given intravenously on day 1, 60 minutes after the pemetrexed infusion, then on day 8. All patients received dexamethasone 4 mg orally twice daily for 3 days starting the day before pemetrexed, vitamin B12 1000 ug intramuscularly 1 week before starting treatment and every 9 weeks and folic acid Ն350 ug orally daily starting 5 to 7 days before treatment, to prevent toxicities associated with pemetrexed. Treatment was continued in the absence of disease progression, provided that patients were clinically benefiting and were tolerating the treatment.
Patient Assessments
Before each cycle, patients had a medical history taken and physical examination. Weekly complete blood counts including white blood cell differential were performed. Serum chemistry including electrolytes; creatinine and liver function tests were performed every 3 weeks. Intercurrent toxicities were assessed before each cycle using the NCI CTCAE V 3.0. Response to therapy was evaluated every two cycles according to the RECIST criteria.
RESULTS
Twenty-seven patients with advanced solid tumors were enrolled in this two-arm phase I trial. Patient characteristics are listed in Table 3 . The median age was 60 years, and most patients had a good performance status. The median number of prior chemotherapy regimens was two; only two Pemetrexed X X Bortezomib X X X chemo-naïve patients were enrolled in the trial. The most common tumor type was NSCLC (59%).
Dose-Limiting Toxicity
In arm A (pemetrexed on day 1 and bortezomib days 1, 4, 8, and 11 every 21 days), no DLTs were observed in three patients enrolled on both dose level 1 and level 2. Three patients were initially enrolled on dose level 3 with no DLTs, and the dose was escalated to dose level 4. Two of three patients on dose level 4 developed grade 3 asthenia. Thus, an additional three patients were treated on dose level 3, and one developed transaminitis (grade 3) and dehydration (grade 3) requiring intravenous fluids (see Table 2 ).
In arm B (pemetrexed on day 1 and bortezomib days 1 and 8 every 21 days), no DLTs were observed in dose levels 1 through 3. There had initially been a dose level 4 (pemetrexed 600 mg/m 2 and bortezomib 1.6 mg/m 2 days 1 and 8), but the protocol was amended because of the toxicity data from arm A at this dose of pemetrexed. Six patients were treated at dose level 3 with no DLTs.
Toxicities
Treatment was generally well tolerated. There were no treatment-related deaths. Clinically significant hematologic toxicities were limited (Table 4 ). Grade 3/4 neutropenia was seen in 12 of 15 patients in arm A and 1 of 12 patients in arm B. Grade 3 anemia was observed in one patient in arm A. There were no episodes of febrile neutropenia or significant bleeding in any patient. Grade 3 non-hematologic toxicities in arm A included one patient with increased transaminases and two patients with fatigue. In arm B, there was one patient with grade 3 weakness. Low-grade transaminitis, renal dysfunction, nausea, and vomiting were also observed more commonly with biweekly dosing. Other common non-hematologic toxicities are outlined in Table 5 .
Recommended Phase II Dose
Based on these findings, the recommended dose in arm A is pemetrexed 500 mg/m 2 on day 1 and bortezomib 1.3 mg/m 2 on days 1, 4, 8, and 11 every 3 weeks. In arm B, the recommended dose is pemetrexed 500 mg/m 2 on day 1 and bortezomib 1.6 mg/m 2 on days 1 and 8 every 21 days. These doses reflect the recommended dosing for both agents when used as single agents in the same schedule. Therefore, the combination requires no dose modification of either drug.
Anti-Tumor Activity
In arm A, there was one patient with a partial response with stage IV NSCLC at dose level 1. He had previously been In arm B, one patient with stage IV NSCLC had a partial response at dose level 3. She had been treated with one prior chemotherapy regimen, carboplatin/paclitaxel for four cycles, followed by cetuximab for 2.5 months on a clinical trial. She received four cycles of pemetrexed and bortezomib and came off of therapy because of atrial fibrillation, deep venous thrombosis, and pulmonary embolus not believed to be related to the study medication. Six patients had stable disease (five NSCLC, one adenoid cystic carcinoma) and five progressed. Among the five patients with NSCLC with stable disease, the duration was 6.4, 2.3, 12.1, 2.8, and 5.9 months.
DISCUSSION
This is the first reported trial combining bortezomib and pemetrexed. This phase I trial was conducted to determine the safety and feasibility of combining pemetrexed and two different schedules of bortezomib. Both schedules of bortezomib and pemetrexed were well tolerated and were able to be administered at recommended single-agent doses. Higher rates of grade 3/4 neutropenia were seen with the twiceweekly bortezomib; however, none of the patients developed febrile neutropenia. Low-grade transaminitis, renal dysfunc-tion, nausea, and vomiting were also observed more commonly with twice weekly dosing, potentially related to the increased total dose of bortezomib.
The feasibility of this combination was evaluated for further development of the combination in a phase II secondline advanced NSCLC trial. Pemetrexed is well established as a therapy in patients with NSCLC. In a large randomized phase III trial, pemetrexed with B12 and folate supplementation was compared with standard second-line docetaxel in patients with previously treated NSCLC. 9 Whereas efficacy was similar, there was less myelosuppression with pemetrexed. Bortezomib has been evaluated in first-and secondline therapy in combination with chemotherapy in advanced NSCLC. A phase II Southwest Oncology Group study (S0339) evaluated bortezomib in combination with carboplatin/gemcitabine in the first-line setting and demonstrated encouraging results with a response rate of 21%, stable disease rate of 45%, and a median survival of 11 months. 10, 11 Predictive markers for bortezomib efficacy remain elusive and an area of ongoing research. 12, 13 Although change in alkaline phosphatase, a marker for osteolytic destruction, from baseline in patients with multiple myeloma was predictive for treatment response and time to progression, it is unlikely to be a reliable predictor in solid tumors. 14 Our study demonstrates that the combination of pemetrexed and bortezomib is feasible and well tolerated in an advanced solid tumor population. In previous solid tumor studies combining chemotherapy with bortezomib, dose escalation has been limited primarily by myelosuppression. Pemetrexed can be delivered at the standard single-agent dose even when given in combination with bortezomib, possibly because it causes comparatively less myelosuppression than other chemotherapeutic agents. The twice-weekly bortezomib regimen in combination with pemetrexed, however, was associated with more neutropenia. The once-weekly regimen seems to have similar efficacy to the twice-weekly regimen and provides a more convenient dosing schedule. Based on its tolerability and preliminary efficacy in NSCLC, a phase II study of pemetrexed in combination with weekly bortezomib is warranted. 
